H. Thomas Watkins

Biopharmaceutical company Human Genome Sciences (NASDAQ: HGSI) agreed Monday to a $3.6 billion takeover bid by GlaxoSmithKline (NYSE: GSK). On Monday, Benzinga reported that GlaxoSmithKline was preparing for the takeover, and that it had offered roughly $14 per share. However, the deal had yet to...